Brookfield stock Is Getting Too Cheap To Ignore!
2 extracted signals · 0 resolved · 2 still active
The Patient InvestorIndependent analyst profile- Source published
- 21 Sept 2026, 18:19 UTC
- Recorded by Tahlil Plus
- 21 Sept 2026, 20:53 UTC
AI-generated source summary
The analysis focuses on Brookfield Corporation (BN) and Brookfield Asset Management (BAM) as potentially undervalued investment opportunities. For BN, the current price of $37.51 is compared to a projected plan value of $67/share, indicating a ~40% margin of safety and suggesting a bullish outlook with a target of $67. The fail bound, below which the bullish thesis would be invalidated, is set at $30. For BAM, the analysis highlights its business model of generating income through asset management, wealth solutions, and other operating businesses, with a significant portion attributed to carried interest. The company's enterprise value is estimated at $150B, with projected distributable earnings per share of $4.90 by 2031, implying a forward P/E of roughly 17x. The analysis suggests that BAM's current valuation might be too low given its growth prospects and the stability of its income streams, which include a substantial portion of non-recourse debt. The target for BAM is inferred based on a potential 17x multiple on its projected EPS, suggesting a target price around $83.30, with a fail bound of $40. The company's strategy of investing in private and growth companies like SpaceX is noted as a driver for future value creation.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
2 signals remain active.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.